Expression and clinical significance of miR‑1 and miR‑133 in pre‑diabetes

Al‑Κafaji,Ghada; Al‑Muhtaresh,Haifa Abdulla; Salem,Abdel Halim

doi:10.3892/br.2021.1409

Expression and clinical significance of miR‑1 and miR‑133 in pre‑diabetes

Authors:
- Ghada Al‑Κafaji
- Haifa Abdulla Al‑Muhtaresh
- Abdel Halim Salem
View Affiliations

Affiliations: Department of Molecular Medicine/Al‑Jawhara Centre for Molecular Medicine, Genetics, and Inherited Disorders, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain, Department of Anatomy, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain
Published online on: February 3, 2021 https://doi.org/10.3892/br.2021.1409
Article Number: 33

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pre‑diabetes represents an intermediate state of altered glucose metabolism between normal glucose levels and type 2 diabetes mellitus (T2D), and is considered a significant risk factor for the development of T2D and related complications. Early detection of pre‑diabetes may allow for the use of timely and effective treatment strategies to prevent its progression. Circulating microRNAs (miRNAs/miRs) that reflect changes in diabetes‑related tissues, including the pancreas, liver, skeletal and heart muscle, and adipose tissue are promising biomarkers of disease progression. In our previous study, it was demonstrated that the cardiac and skeletal muscle specific miR‑1 and miR‑133 are upregulated in the blood of patients with T2D and cardiovascular disease. Since both miRNAs have been shown to be implicated in insulin resistance, an important feature of pre‑diabetes, we hypothesised that their expression may be increased prior to clinical diagnosis of T2D, and may thus serve as biomarkers for pre‑diabetes. The expression levels of circulating miRNAs were evaluated by reverse transcription‑quantitative PCR in whole blood samples from 55 subjects, including 28 pre‑diabetes individuals with impaired fasting glucose (FG) and impaired glucose tolerance, and 27 healthy controls. The individuals with pre‑diabetes exhibited significantly higher expression levels of miR‑1 and miR‑133 compared with the controls (P<0.05). Target prediction search revealed that both miR‑1 and miR‑133 target several pathways involved in the pathophysiology of diabetes. Pearson's correlation analysis revealed that the two miRNAs were positively correlated with blood glucose parameters, including FG, 2‑h oral glucose tolerance test and glycated haemoglobin A1c levels, as well as with insulin resistance (P<0.05). Multivariate logistic regression analysis revealed that the two miRNAs were significantly and directly associated with pre‑diabetes, and this association remained significant after adjustment for several confounding variables (P<0.05). Moreover, linear regression analysis showed that the Homeostatic Model Assessment‑Insulin Resistance was the only significant predictor to be significantly associated with both miRNAs (P<0.05). In discriminating pre‑diabetes individuals from healthy controls, the area under the curves (AUCs) of the receiver operating characteristic curves (ROCs) were 0.813 and 0.810 for miR‑1 and miR‑133 respectively (P<0.05). Despite the relatively small number of participants, the present study showed for the first time that circulating levels of miR‑1 and miR‑133 were increased in individuals with pre‑diabetes, and they were associated with important features of pre‑diabetes. Thus, they may serve as clinical biomarkers for the early-stages of T2D.

View Figures

View References

1	Di Pino A, Urbano F, Piro S, Purrello F and Rabuazzo AM: Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk. World J Diabetes. 7:423–432. 2016.PubMed/NCBI View Article : Google Scholar
2	Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R and Zinman B: American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care. 30:753–759. 2007.PubMed/NCBI View Article : Google Scholar
3	Tabák AG, Herder C, Rathmann W, Brunner EJ and Kivimäki M: Prediabetes: a high-risk state for diabetes development. Lancet. 379:2279–2290. 2012.PubMed/NCBI View Article : Google Scholar
4	DeFronzo RA and Abdul-Ghani M: Assessment and treatment of cardiovascular risk in prediabetes: Impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 108 (Suppl 3):3B–24B. 2011.PubMed/NCBI View Article : Google Scholar
5	Huang Y, Cai X, Mai W, Li M and Hu Y: Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 355(i5953)2016.PubMed/NCBI View Article : Google Scholar
6	Brannick B, Wynn A and Dagogo-Jack S: Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 241:1323–1331. 2016.PubMed/NCBI View Article : Google Scholar
7	Abdul-Ghani MA and DeFronzo RA: Pathophysiology of prediabetes. Curr Diab Rep. 9:193–199. 2009.PubMed/NCBI View Article : Google Scholar
8	Bergman M: Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine. 43:504–513. 2013.PubMed/NCBI View Article : Google Scholar
9	Fonseca VA: Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 Suppl. 2 (Suppl 2):S151–S156. 2009.PubMed/NCBI View Article : Google Scholar
10	Tuso P: Prediabetes and lifestyle modification: Time to prevent a preventable disease. Perm J. 18:88–93. 2014.PubMed/NCBI View Article : Google Scholar
11	Portero McLellan KC, Wyne K, Villagomez ET and Hsueh WA: Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag. 10:173–188. 2014.PubMed/NCBI View Article : Google Scholar
12	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
13	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006.PubMed/NCBI View Article : Google Scholar
14	Bartel DP: MicroRNA: Target recognition and regulatory functions. Cell. 136:215–233. 2009.PubMed/NCBI View Article : Google Scholar
15	Tang X, Tang G and Ozcan S: Role of microRNAs in diabetes. Biochim Biophys Acta. 1779:697–701. 2008.PubMed/NCBI View Article : Google Scholar
16	Deng J and Guo F: MicroRNAs and type 2 diabetes. ExRNA. 1(36)2019.
17	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008.PubMed/NCBI View Article : Google Scholar
18	Chen X, Liang H, Zhang J, Zen K and Zhang CY: Secreted microRNAs: A new form of intercellular communication. Trends Cell Biol. 22:125–132. 2012.PubMed/NCBI View Article : Google Scholar
19	Vienberg S, Geiger J, Madsen S and Dalgaard LT: MicroRNAs in metabolism. Acta Physiol (Oxf). 219:346–361. 2017.PubMed/NCBI View Article : Google Scholar
20	Jiménez-Lucena R, Camargo A, Alcalá-Diaz JF, Romero-Baldonado C, Luque RM, van Ommen B, Delgado-Lista J, Ordovás JM, Pérez-Martínez P, Rangel-Zúñiga OA and López-Miranda J: A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. J Exp Mol Med. 50:1–12. 2018.PubMed/NCBI View Article : Google Scholar
21	Al-Kafaji G, Al-Mahroos G, Alsayed NA, Hasan ZA, Nawaz S and Bakhiet M: Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol Med Rep. 12:7485–7490. 2015.PubMed/NCBI View Article : Google Scholar
22	Al-Muhtaresh H and Al-Kafaji G: Evaluation of two-diabetes related microRNAs suitability as earlier blood biomarkers for detecting prediabetes and type 2 diabetes mellitus. J Clin Med. 7(12)2018.PubMed/NCBI View Article : Google Scholar
23	Zhang T, Li L, Shang Q, Lv C, Wang C and Su B: Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. Biochem Biophys Res Commun. 463:60–63. 2015.PubMed/NCBI View Article : Google Scholar
24	Al-Muhtaresh HA, Salem AH and Al-Kafaji G: Upregulation of circulating cardiomyocyte-enriched miR-1 and miR-133 associate with the risk of coronary artery disease in type 2 diabetes patients and serve as potential biomarkers. J Cardiovasc Transl Res. 12:347–357. 2019.PubMed/NCBI View Article : Google Scholar
25	Mitchelson KR and Qin WY: Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease. World J Biol Chem. 6:162–208. 2015.PubMed/NCBI View Article : Google Scholar
26	DeFronzo RA and Tripathy D: Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 32 (Suppl 2):S157–S163. 2009.PubMed/NCBI View Article : Google Scholar
27	Granjon A, Gustin MP, Rieusset J, Lefai E, Meugnier E, Güller I, Cerutti C, Paultre C, Disse E, Rabasa-Lhoret R, et al: The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway. Diabetes. 58:2555–2564. 2009.PubMed/NCBI View Article : Google Scholar
28	de Gonzalo-Calvo D, van der Meer RW, Rijzewijk LJ, Smit JW, Revuelta-Lopez E, Nasarre L, Escola-Gil JC, Lamb HJ and Llorente-Cortes V: Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci Rep. 7(47)2017.PubMed/NCBI View Article : Google Scholar
29	Delic D, Eisele C, Schmid R, Luippold G, Mayoux E and Grempler R: Characterization of micro-RNA changes during the progression of type 2 diabetes in zucker diabetic fatty rats. Int J Mol Sci. 17(665)2016.PubMed/NCBI View Article : Google Scholar
30	World Health Organization (WHO): Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. WHO, Geneva, 2006. https://apps.who.int/iris/handle/10665/43588?locale%E2%80%91attribute=es&show=full. Accessed June 16, 2012.
31	American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 33 (Suppl 1):S62–S69. 2010.PubMed/NCBI View Article : Google Scholar
32	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985.PubMed/NCBI View Article : Google Scholar
33	Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006.PubMed/NCBI View Article : Google Scholar
34	Horak M, Novak J and Bienertova-Vasku J: Muscle-specific microRNAs in skeletal muscle development. Dev Biol. 410:1–13. 2016.PubMed/NCBI View Article : Google Scholar
35	Colpaert RMW and Calore M: MicroRNAs in cardiac diseases. Cells. 8(737)2019.PubMed/NCBI View Article : Google Scholar
36	Chen JF, Callis TE and Wang DZ: microRNAs and muscle disorders. J Cell Sci. 122 (Pt 1):13–20. 2009.PubMed/NCBI View Article : Google Scholar
37	Frias Fde T, de Mendonça M, Martins AR, Gindro AF, Cogliati B, Curi R and Rodrigues AC: MyomiRs as markers of insulin resistance and decreased myogenesis in skeletal muscle of diet-induced obese mice. Front Endocrinol (Lausanne). 7(76)2016.PubMed/NCBI View Article : Google Scholar
38	Huang MB, Xu H, Xie SJ, Zhou H and Qu LH: Insulin-like growth factor-1 receptor is regulated by microRNA-133 during skeletal myogenesis. PLoS One. 6(e29173)2011.PubMed/NCBI View Article : Google Scholar
39	Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, Cimino V, De Marinis L, Frustaci A, Catalucci D and Condorelli G: Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 120:2377–2385. 2009.PubMed/NCBI View Article : Google Scholar
40	Clemmons DR: Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 41:425–443, vii-viii. 2012.PubMed/NCBI View Article : Google Scholar
41	Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE and Strickler HD: The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 25:3–12. 2009.PubMed/NCBI View Article : Google Scholar
42	Dunger D, Yuen K and Ong K: Insulin-like growth factor I and impaired glucose tolerance. Horm Res. 62 (Suppl 1):101–107. 2004.PubMed/NCBI View Article : Google Scholar
43	Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB and Wareham NJ: Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet. 359:1740–1745. 2002.PubMed/NCBI View Article : Google Scholar
44	Aguirre GA, De Ita JR, de la Garza RG and Castilla-Cortazar I: Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 14(3)2016.PubMed/NCBI View Article : Google Scholar
45	Siracusa J, Koulmann N and Banzet S: Circulating myomiRs: A new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle. 9:20–27. 2018.PubMed/NCBI View Article : Google Scholar
46	Seok H, Lee H, Lee S, Ahn SH, Lee HS, Kim GD, Peak J, Park J, Cho YK, Jeong Y, et al: Position-specific oxidation of miR-1 encodes cardiac hypertrophy. Nature. 584:279–285. 2020.PubMed/NCBI View Article : Google Scholar
47	Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Gil MJ, Valentí V, Rotellar F, Ramírez B, Salvador J, et al: Body adiposity and type 2 diabetes: Increased risk with a high body fat percentage even having a normal BMI. Obesity (Silver Spring). 19:1439–1444. 2011.PubMed/NCBI View Article : Google Scholar
48	Khaodhiar L, Cummings S and Apovian CM: Treating diabetes and prediabetes by focusing on obesity management. Curr Diab Rep. 9:348–354. 2009.PubMed/NCBI View Article : Google Scholar